{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:32:13Z","timestamp":1794724333958,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["9039-00026B"],"award-info":[{"award-number":["9039-00026B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.atherosclerosis.2023.117236","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:32:26Z","timestamp":1691627546000},"page":"117236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type"],"prefix":"10.1016","volume":"394","author":[{"given":"Louise E.","family":"Bechmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Emanuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Benn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.117236_bib1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp. Pract."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib3","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"2022","key":"10.1016\/j.atherosclerosis.2023.117236_bib6","first-page":"4","volume":"24","author":"McDonagh","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"2022","key":"10.1016\/j.atherosclerosis.2023.117236_bib7","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib8","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ccl.2015.01.005","article-title":"Dyslipidemia in special ethnic populations","volume":"33","author":"Pu","year":"2015","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib13","unstructured":"J. Higgins, T. Li, J. Deeks, Chapter 6: Choosing effect measures and computing estimates of effect, in: Cochrane, n.d. https:\/\/training.cochrane.org\/handbook\/current\/chapter-06."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib14","series-title":"Stochastically Dependent Effect Sizes","first-page":"357","author":"Gleser","year":"2009"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (Low-Density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib19","first-page":"1","article-title":"Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus","volume":"6","author":"Bando","year":"2016","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib20","doi-asserted-by":"crossref","first-page":"III2","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26598","article-title":"Small dense low-density lipoprotein cholesterol and ischemic stroke","author":"Balling","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MOL.0000000000000824","article-title":"Small dense low-density lipoprotein particles: clinically relevant?","volume":"33","author":"Krauss","year":"2022","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib25","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib26","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","author":"von Eckardstein","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib27","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.molmed.2019.05.010","article-title":"ANGPTL4 in metabolic and cardiovascular disease","volume":"25","author":"Aryal","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.117.310269","article-title":"Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: two cohort studies of 113 554 individuals","volume":"38","author":"Varbo","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC. Heart fail."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib31","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"JLR (J. Lipid Res.)"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib32","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvz017","article-title":"Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED)","volume":"4","author":"Zainordin","year":"2020","journal-title":"J. Endocrine Soc."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib33","doi-asserted-by":"crossref","unstructured":"M. Lin, Y. Shan, X. Hu, H. Zhou, Z. Chen, et al., Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis, (n.d.). https:\/\/doi.org\/10.21203\/rs.3.rs-2270625\/v1.","DOI":"10.21203\/rs.3.rs-2270625\/v1"},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group","volume":"15","author":"Wilson","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117236_bib36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium glucose cotransporter 2 inhibitors treatment: a meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J. Diabetes Invest."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023051535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023051535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:57:04Z","timestamp":1723737424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023051535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":35,"alternative-id":["S0021915023051535"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117236","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117236"}}